Sino Biopharmaceutical

Sino Biopharmaceutical SBHMY Stock

$14.40   0.000000%
Add to favorites
Market Cap
$12.80B
LOW - HIGH [24H]
$14.23 - $14.40
VOLUME [24H]
$200.00
P/E Ratio
37.89
Earnings per share
$0.38
ISIN
US82937X1037
Price   Prediction

Sino Biopharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Sino Biopharmaceutical (SBHMY) stock price today is 14.4 USD on OTC Markets OTCPK (0% on the day). Updated .

Sino Biopharmaceutical SBHMY Financial and Trading Overview

Sino Biopharmaceutical stock price 14.4 USD
Previous Close 14.4 USD
Open 14.23 USD
Bid 12.48 USD x 20000
Ask 12.93 USD x 10000
Day's Range 14.23 - 14.4 USD
52 Week Range 11.27 - 19.45 USD
Volume 200 USD
Avg. Volume 760 USD
Market Cap 12.8B USD
Beta (5Y Monthly) 0.656
PE Ratio (TTM) 37.894737
EPS (TTM) 0.38 USD
Forward Dividend & Yield 0.31 (2.13%)
Ex-Dividend Date September 2, 2026
1y Target Est N/A

SBHMY Valuation Measures

Enterprise Value 16.12B USD
Trailing P/E 37.894737
Forward P/E N/A
PEG Ratio (5 yr expected) 0.71
Price/Sales (ttm) 0.37992078
Price/Book (mrq) 2.634686
Enterprise Value/Revenue 0.478
Enterprise Value/EBITDA 1.543

Trading Information

Sino Biopharmaceutical Stock Price History

Beta (5Y Monthly) 0.656
52-Week Change -25.94%
S&P500 52-Week Change 3.06%
52 Week High 19.45 USD
52 Week Low 11.27 USD
50-Day Moving Average 14.16 USD
200-Day Moving Average 14.08 USD

SBHMY Share Statistics

Avg. Volume (3 month) 760 USD
Avg. Daily Volume (10-Days) 40 USD
Shares Outstanding 889.23M
Float 436.69M
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0.105
Trailing Annual Dividend Yield 0.72%
5 Year Average Dividend Yield 183.00%
Payout Ratio 0.6803
Last Split Factor 1.5:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 7.08%
Operating Margin (ttm) 28.17%
Gross Margin 82.42%
EBITDA Margin 30.99%

Management Effectiveness

Return on Assets (ttm) 7.50%
Return on Equity (ttm) 14.06%

Income Statement

Revenue (ttm) 33.7B USD
Revenue Per Share (ttm) 37.46 USD
Quarterly Revenue Growth (yoy) 10.59%
Gross Profit (ttm) 27.78B USD
EBITDA 10.45B USD
Net Income Avi to Common (ttm) 2.39B USD
Diluted EPS (ttm) 0.38
Quarterly Earnings Growth (yoy) 1.40%

Balance Sheet

Total Cash (mrq) 27.58B USD
Total Cash Per Share (mrq) 30.92 USD
Total Debt (mrq) 17.17B USD
Total Debt/Equity (mrq) 37.13 USD
Current Ratio (mrq) 1.63
Book Value Per Share (mrq) 5.4655466

Cash Flow Statement

Operating Cash Flow (ttm) 10.45B USD
Levered Free Cash Flow (ttm) 5.22B USD

Profile of Sino Biopharmaceutical

Country United States
State N/A
City Wan Chai
Address Unit 09, Office Tower
ZIP N/A
Phone 852 2802 9886
Website https://www.sbpgroup.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 22838

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Q&A For Sino Biopharmaceutical Stock

What is a current SBHMY stock price?

Sino Biopharmaceutical SBHMY stock price today per share is 14.4 USD.

How to purchase Sino Biopharmaceutical stock?

You can buy SBHMY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sino Biopharmaceutical?

The stock symbol or ticker of Sino Biopharmaceutical is SBHMY.

Which industry does the Sino Biopharmaceutical company belong to?

The Sino Biopharmaceutical industry is Biotechnology.

How many shares does Sino Biopharmaceutical have in circulation?

The max supply of Sino Biopharmaceutical shares is 889.23M.

What is Sino Biopharmaceutical Price to Earnings Ratio (PE Ratio)?

Sino Biopharmaceutical PE Ratio is 37.89473700 now.

What was Sino Biopharmaceutical earnings per share over the trailing 12 months (TTM)?

Sino Biopharmaceutical EPS is 0.38 USD over the trailing 12 months.

Which sector does the Sino Biopharmaceutical company belong to?

The Sino Biopharmaceutical sector is Healthcare.

$2.08T
Total marketcap
$58.85B
Total volume
BTC 58.74%   •   ETH 10.08%
Dominance
Select currency